SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-DLL3-Anti-CD3 Bispecific Molecule

Catalog: 102209
Lot: 240404

Product Information

Description:	Anti-DLL3-Anti-CD3 Bispecific Molecule is a purified recombinant human bispecific molecule with T cell Engager. This bispecific molecule has been tested for specific activity in a functional reporter assay using NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) co-cultured with DLL3 CHO Cell Line (BPS Bioscience #78882).
Background:	DLL3, also known as delta like ligand three, is a Notch ligand characterized by a DSL domain, transmembrane region, and a series of EGF repeats. Notch ligands can participate in trans-interactions (interaction with Notch receptor on a different cell) and cis interactions (interaction with Notch receptor within the same cell) to activate or inhibit Notch signaling, respectively. DLL3 exclusively functions to inhibit Notch signaling through cis inhibition. While DLL3 expression is limited in healthy tissue, high expression levels of DLL3 are found in various cancers including small cell lung cancer (SCLC), where it plays an oncogenic role. Relieving DLL3-mediated inhibition of Notch signaling may serve as a therapeutic avenue, with drugs being developed to target DLL3 as a possible lung cancer therapy (example: rovalpituzumab tesirine).
Species:	Human
Concentration:	0.43 mg/ml
Isotype:	IgG1
Clonality:	Monoclonal
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	105 kDa + glycans
Glycosylation:	This molecule runs at a higher MW by SDS-PAGE due to glycosylation.
Stability:	At least 12 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	NFAT Luciferase Reporter Jurkat cells (BPS Bioscience #60621) were incubated with increasing concentrations of Anti DLL3-Anti-CD3 Bispecific Molecule in the presence of DLL3 CHO cells (BPS Bioscience #78882) or CHO cells (ATCC #CCL-61™). Luciferase activity was measured using ONE-Step™ Luciferase Assay System (BPS Bioscience #60690).
Applications:	The Anti-DLL3-Anti-CD3 Bispecific Molecule can be used for studying DLL3^{+} cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621).

Anti-DLL3-Anti-CD3 Bispecific Molecule

Catalog: 102209
Lot: 240404

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Activation of NFAT Jurkat Reporter by Anti-DLL3-Anti-CD3 Molecule